Isavuconazole for the Treatment of Fungal Infections: A Real-life Experience From the Fungal Infection Network of Switzerland (FUNGINOS)

Jade Couchepin; Ilana Reinhold; Ilona Kronig; Monia Guidi; Thierry Buclin; Peter W Schreiber; Dionysios Neofytos; Frederic Lamoth; Fungal Infection Network of Switzerland (FUNGINOS)

doi:10.1093/ofid/ofae223

Isavuconazole for the Treatment of Fungal Infections: A Real-life Experience From the Fungal Infection Network of Switzerland (FUNGINOS)

Open Forum Infect Dis. 2024 Apr 26;11(5):ofae223. doi: 10.1093/ofid/ofae223. eCollection 2024 May.

Authors

Collaborators

Affiliations

¹ Infectious Diseases Service, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
² Department of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich and University of Zurich, Zurich, Switzerland.
³ Division of Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland.
⁴ Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
⁵ Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.
⁶ Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
⁷ Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Abstract

This analysis of 116 isavuconazole therapy courses shows that hepatic test disturbances (HTDs) were relatively frequent (29% of cases) but rarely led to treatment interruption (5%). Importantly, patients with baseline HTDs, including those attributed to a first-line triazole, did not exhibit a higher risk of subsequent HTD under isavuconazole therapy.

Keywords: aspergillosis; hepatotoxicity; liver; mucormycosis; triazoles.